GO
Loading...

Pharmacyclics Inc

More

  • That has focused attention on other AbbVie drugs with blockbuster potential, including Viekira Pak, a new hepatitis C medication approved in the U.S. in December. But U.S. sales of $138 million in the first quarter came in below expectations of $215 million, on average, according to survey figures cited by analyst Robyn Karnauskas of Deutsche Bank.

  • April 23- U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira. Sales of AbbVie's all-oral hepatitis C treatment Viekira Pak, approved by U.S. regulators in December, came in at $231 million. AbbVie raised its full-year adjusted profit forecast to $4.10- $4.30 per share, from...

  • April 21- Some of the top investors at Mylan NV, including Paulson& Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter. Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania- based company.

  • Cramer Remix: Oil news you've been waiting for Wednesday, 18 Mar 2015 | 7:34 PM ET
    Jim Cramer on Mad Money.

    You’ve been waiting months for the answer on oil, “Mad Money” host Jim Cramer’s got the answer.

  • Cramer: This sector has tons of hidden opportunity Monday, 16 Mar 2015 | 6:17 PM ET
    Biotech

    Jim Cramer is seeing an unusual trend in the market lately, which has set these stocks on fire.

  • March 16- An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson& Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs. Pharmacyclics, which recently agreed to be acquired by AbbVie Inc for about $21 billion, said Imbruvica showed a...

  • March 16- An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson& Johnson's Imbruvica, after the treatment was successful in treating two types of cancer in combination with other drugs. Pharmacyclics, which recently agreed to be acquired by AbbVie Inc, said Imbruvica showed a statistically significant...

  • March 16- An independent panel to the U.S. Food and Drug Administration recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson& Johnson's Imbruvica, after the treatment was successful in treating two types of cancer in combination with other drugs. Pharmacyclics, which recently agreed to be acquired by AbbVie Inc, said Imbruvica...

  • Cramer: This X factor is ignored in your portfolio Thursday, 5 Mar 2015 | 6:13 PM ET
    A Costco store in Alhambra, Calif.

    Jim Cramer sees one portfolio x factor that could change your stock perspective from overvalued to underestimated.

  • US STOCKS-Wall St up slightly ahead of jobs report Thursday, 5 Mar 2015 | 3:15 PM ET

    *AbbVie to buy Pharmacyclics for about $21 bln. NEW YORK, March 5- U.S. stocks were modestly higher on Thursday after two days of declines as investors held back on big bets ahead of Friday's jobs report, which is expected to be a big factor in influencing the timing of a Federal Reserve interest rate hike. "People are taking a wait-and-see approach ahead of the jobs...

  • US STOCKS-Wall St little changed after 2-day drop, data Thursday, 5 Mar 2015 | 11:29 AM ET

    *AbbVie to buy Pharmacyclics for about $21 bln. NEW YORK, March 5- U.S. stocks were little changed on Thursday, in the wake of two days of declines on the S&P 500, as economic data did little to alter expectations on the timing of an interest rate hike by the Federal Reserve. "There is nothing really to drive sentiment one way or the other that is going to change people's...

  • *AbbVie to buy Pharmacyclics for about $21 bln. NEW YORK, March 5- U.S. stocks were little changed on Thursday, in the wake of two days of declines on the S&P 500, as gains were curbed by a higher-than-expected initial jobless claims report ahead of a report on factory orders. "That's a bit of an uptick because we've been pretty consistently in the upper 200,000 range,"...

  • *AbbVie to buy Pharmacyclics for about $21 bln. *Costco climbs in premarket after results. "That's a bit of an uptick because we've been pretty consistently in the upper 200,000 range," said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois.

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...

  • Early movers: PCYC, COST, MCD, AAPL & more Thursday, 5 Mar 2015 | 7:50 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *AbbVie to buy Pharmacyclics for about $21 bln. *Costco climbs in premarket after results. NEW YORK, March 5- U.S. stock index futures edged up on Thursday, after two days of declines on the S&P 500, ahead of data on the labor market and factory orders.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday on the Nasdaq. Pharmacyclics stockholders can elect cash, AbbVie stock or a combination, subject to proration, the company said in a statement. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated...

  • AbbVie to buy Pharmacyclics in $21 billion deal Wednesday, 4 Mar 2015 | 11:13 PM ET

    Drugmaker AbbVie said it will buy Pharmacyclics for about $21 billion to boost its oncology drugs pipeline.